{"classes":[{"categories":[{"measurements":[{"comment":"Full range is not evaluable for a single participant. Median value presented here is the actual titer value for this single participant.","groupId":"OG000","lowerLimit":"NA","upperLimit":"NA","value":"200"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"1"}],"units":"Participants"}],"description":"Serum samples were collected and tested for the presence of antibodies against belantamab mafodotin . Confirmed positive ADA samples were further analyzed to obtain the titer of the antibodies. Titers of anti-drug antibodies against belantamab mafodotin is presented.","dispersionType":"Full Range","groups":[{"description":"Participants with relapsed/refractory multiple myeloma (RRMM) received 30 minutes intravenous infusion of 2.5 milligram/kilogram (mg/kg) belantamab mafodotin on day 1 of each 21-day cycle","id":"OG000","title":"Belantamab Mafodotin"}],"paramType":"MEDIAN","populationDescription":"Safety Population. Data for only that participant with positive ADA results is presented.","reportingStatus":"POSTED","timeFrame":"Up to approximately 263 weeks","title":"Titers of ADAs Against Belantamab Mafodotin","type":"SECONDARY","unitOfMeasure":"Titer"}